10.27.16
Mayne Pharma has launched budesonide capsules in a 3 mg dose in the U.S. Budesonide is a generic alternative to Entocort EC, which is used as a treatment for patients with mild to moderate Crohn’s disease.
“This latest addition to Mayne Pharma’s fast-growing generic portfolio reflects the company’s core strengths in complex drug delivery formulations and technologies,” said Stefan Cross, president, Mayne Pharma USA. “This expertise paves the way to creating more high-quality generic alternatives that ultimately provide patients with greater choices, better access and more affordable solutions for their improved health.”
According to IMS Health, branded and generic sales of budesonide in the U.S. were approximately $322 million for the 12 months ending Aug. 31.
Mayne Pharma markets more than 50 products and has a growing pipeline of more than 40 generic and branded drug products for the U.S. market representing IMS Health sales greater than $7 billion. Currently, Mayne Pharma has 19 product applications pending at the U.S. Food and Drug Administration.
“This latest addition to Mayne Pharma’s fast-growing generic portfolio reflects the company’s core strengths in complex drug delivery formulations and technologies,” said Stefan Cross, president, Mayne Pharma USA. “This expertise paves the way to creating more high-quality generic alternatives that ultimately provide patients with greater choices, better access and more affordable solutions for their improved health.”
According to IMS Health, branded and generic sales of budesonide in the U.S. were approximately $322 million for the 12 months ending Aug. 31.
Mayne Pharma markets more than 50 products and has a growing pipeline of more than 40 generic and branded drug products for the U.S. market representing IMS Health sales greater than $7 billion. Currently, Mayne Pharma has 19 product applications pending at the U.S. Food and Drug Administration.